Attached Carole Ho - 15 Feb 2023 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role
Chief Medical Officer
Signature
/s/ Tyler Nielsen, by power of attorney
Issuer symbol
DNLI
Transactions as of
15 Feb 2023
Net transactions value
-$43,394
Form type
4
Filing time
17 Feb 2023, 15:20:50 UTC
Previous filing
14 Feb 2023
Next filing
12 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DNLI Common Stock Sale $43,394 -1,476 -0.8% $29.40 182,809 15 Feb 2023 See footnote F1, F2
holding DNLI Common Stock 25,000 15 Feb 2023 See footnote F3
holding DNLI Common Stock 119,749 15 Feb 2023 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
F2 The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F3 The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
F4 Includes 119,339 RSUs.